We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (125)1/16/2003 11:44:42 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 146
Pretty sucky, overall.

Perhaps JNJ doesn't mention the potential of their molecules for a reason? In the history of biotech, there's never been a lousier partner than JNJ. For all we know, they've sand bagged Centocor.

The upside? Scratch one more management team that didn't have a concept of the breadth of the job that needed doing. They did the job, as they conceived of it, pretty well. But that's not enough.

Silly decision to fill the pipe with a molecule that needed so much preclinical, and a molecule that didn't fit the infrastructure, at that.

To: mopgcw who wrote (125)1/16/2003 11:54:11 AM
From: keokalani'nui  Read Replies (1) | Respond to of 146
Highly doubtful, but never say never. Too late for me anyway, all gone.